ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - RETAPRNewsWire • 10/23/20
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 14, 2020 - RETANewsfile Corp • 10/23/20
RETA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Reata Pharmaceuticals, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the FirmBusiness Wire • 10/22/20
RETA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 14, 2020 in the Class Action Filed on Behalf of Reata Pharmaceuticals, Inc. Limited ShareholdersNewsfile Corp • 10/22/20
Rosen, A Globally Recognized Law Firm, Announces Filing of Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - RETANewsfile Corp • 10/21/20
RETA CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit has been Filed Against Reata Pharmaceuticals Inc.PRNewsWire • 10/21/20
ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Reata Pharmaceuticals, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm – RETABusiness Wire • 10/19/20
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 10/19/20
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 10/16/20
Reata Pharmaceuticals, Inc. Announces Presentation of KIDNEYCODE Program at the American Society of Nephrology Kidney Week 2020 ReimaginedGlobeNewsWire • 10/15/20
Reata Pharmaceuticals, Inc. (RETA) Down 6.2% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/09/20
Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich’s Ataxia at the American Academy of NeurologyGlobeNewsWire • 09/03/20
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20
Reata Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development ProgramsGlobeNewsWire • 08/10/20
Reata Pharmaceuticals, Inc. to Report Second Quarter 2020 Financial Results and to Provide an Update on Development Programs on August 10, 2020GlobeNewsWire • 08/03/20
Reata Announces Initiation of Investigator-Sponsored Study Evaluating Bardoxolone for Complications Associated with COVID-19GlobeNewsWire • 07/28/20
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Reata Pharmaceuticals, Inc.- RETANewsfile Corp • 07/03/20
Reata Pharmaceuticals, Inc. Closes $350 Million Strategic Investment From Blackstone Life SciencesGlobeNewsWire • 06/24/20
